Krakow, Poland – 09 May 2019 – Selvita, one of the largest providers of drug discovery services in Europe, announced today the appointment of Tom Coulter, to the role of Integrated Drug Discovery Director.
Dr. Coulter has joined Selvita in May and will be responsible for the scientific progress and execution of integrated drug discovery projects performed by Selvita.
Tom Coulter is a seasoned medicinal chemist, with thorough experience in the overall drug discovery cycle. His professional experience includes a sixteen-year tenure at Evotec, where he was VP Medicinal Chemistry and Senior VP Drug Discovery, as well as managerial chemistry and drug discovery positions at several British biotech companies incl. Syntaxin, Karus Therapeutics and Midatech Pharma. His achievements include management of multiple drug discovery programs delivering 15 IND-stage molecules.
Dr. Coulter has experience in managing both chemists and biologists. His expertise in terms of therapeutic areas is broad and includes oncology, inflammation including immunomodulation, anti-infectives, metabolic disease, CNS and more. He led variety of drug discovery programmes from small molecule to biologic drug discovery, as well as drug delivery technology.
– We are thrilled to have Tom Coulter join the senior management team at Selvita. The wealth of experience he brings in to our company is invaluable. We strongly believe that his strategic thinking and thorough experience will not only allow to speed up the integrated project cycle and progress, but will also significantly contribute to the number of IND stage molecules generated by Selvita for our customers – comments Edyta Jaworska, Management Board Member at Selvita.
Selvita Services Segment
Selvita Services Segment is a drug discovery and development partner for the pharmaceutical and biotechnology industries. It provides integrated drug discovery support starting from hit identification, hit to lead, lead optimization phase up to nomination of a preclinical candidate. The broad range of services includes medicinal and computational chemistry, custom synthesis and scale-up, in vitro pharmacology, structural biology, protein chemistry, ADME/DMPK as well as a comprehensive offer of analytical testing for APIs and drug products. In addition, Selvita Services Segment has extensive expertise in comparability studies of biosimilar drugs. Its laboratories are both GLP- and GMP-certified.
Selvita S.A. is a clinical stage drug discovery company engaged in the research and development of novel cancer therapies, as well as provision of integrated drug discovery services. Selvita is headquartered in Krakow, Poland, with offices in the U.S. (Greater Boston, San Francisco Bay), and U.K. (Cambridge). Selvita has currently several projects at the early or late discovery stage. Drug discovery clients of Selvita include numerous large and medium-sized pharmaceutical and biotechnology companies from the U.S. and Europe. The company is listed on the Warsaw Stock Exchange (WSE:SLV).
+48 784 069 418